Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia (ASSOMYP)
Primary Purpose
Myopia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
blood sample
Sponsored by
About this trial
This is an interventional basic science trial for Myopia focused on measuring high myopia
Eligibility Criteria
Inclusion Criteria:
- high myopic (cases) volunteers,
- emmetropic (controls) volunteers
Exclusion Criteria:
- syndromic myopic children under 18 years,
- non autonomous adults
Sites / Locations
- CHU Pointe-à-Pitre
- CHU Bordeaux Hôpital Pellegrin
- CHU Limoges Hôpital Dupuytren
- CHU Toulouse Hôpital Purpan
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Emmetropic volunteers
High myopic volunteers
Arm Description
Blood sample
Blood sample
Outcomes
Primary Outcome Measures
Numbers of allele frequencies at markers in the population
Numbers of allele frequencies at markers in the population
Secondary Outcome Measures
Full Information
NCT ID
NCT02583620
First Posted
August 18, 2015
Last Updated
October 20, 2015
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT02583620
Brief Title
Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia
Acronym
ASSOMYP
Official Title
Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Compelling evidence of genetic components in high myopia has been put forward by several studies. Twin cohorts, familial linkage studies and population studies has described at least 10 loci containing genes involved in the disease development. The investigators previously demonstrated novel linkage on chromosome 7q36 and chromosome 7p15 in French families. A new approach consisting of a case-control based population association study is underway in order to recover a high number of myopic subjects avoiding the limitation of familial cases. 1.8 millions polymorphic markers will be compared with emmetropic controls in order to recover loci associated with the disease in the population.
Detailed Description
Myopia is a worldwide refractive ocular disorder and is the most frequent visual defect in man. It is responsible for a major health problem, affecting around 25% of the western population. High myopia is the most severe form of the myopic spectrum and is defined by an increase of refractive error beyond -5 dioptres. About 2.5% of the general population suffers from this, while the secondary complications are responsible among these patients for the 4th cause of legal blindness. The physiopathology of myopia remains unknown and mechanisms leading to the disease are most probably complex, mixing acquired environmental and genetics factors. Our team in a previous study gathered and analysed an important series of high myopic families: Heritability, segregation and linkage analyses modelling the transmission mode localised two major genomic regions linked to high myopia susceptibility on chromosome 7q36 and chromosome 7p15. Several loci have been described by other teams working on the same topic among different human populations. Very recently reappraisal of 55 families led to the delineation of a complex segregation model of the high myopia phenotype thus claiming an oligo- polygenic mode of transmission. Together these results express the need to collect more cases and to substitute an linkage studies by association studies already conducted in order to increase the power to detect involved loci.
To find one or more genomic loci involved in high myopia susceptibility; a polygenic model and association analysis is considered a referent method to decipher the participation of multiple, low acting loci. High density SNPs/CNVs DNA markers covering the whole genome will be used for genotyping.
Phenotypes including ophthalmologic evaluation, ethno-geographic origin and familial data will be collected in order to allow further stratification or clustering.
Computing of the statistical power of the association analysis conducted to minimize the number of false positive associations and to obtain a 80% of detection power indicated the need of 400 high myopic subjects and 400 controls to be analysed.
Collaboration between a Clinical Investigation Center (CIC) and Ophthalmology clinics will be used to overcome recruitment problems. DNA extraction and genotyping will be conducted in Institut national de la santé et de la recherche (INSERM-UPS) unit in Toulouse using the "Toulouse's Génopole" microarrays genotyping facilities.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia
Keywords
high myopia
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
553 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Emmetropic volunteers
Arm Type
Other
Arm Description
Blood sample
Arm Title
High myopic volunteers
Arm Type
Other
Arm Description
Blood sample
Intervention Type
Genetic
Intervention Name(s)
blood sample
Intervention Description
A blood test is realized on the subject
Primary Outcome Measure Information:
Title
Numbers of allele frequencies at markers in the population
Description
Numbers of allele frequencies at markers in the population
Time Frame
Baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
high myopic (cases) volunteers,
emmetropic (controls) volunteers
Exclusion Criteria:
syndromic myopic children under 18 years,
non autonomous adults
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
François MALECAZE, PhD, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Pointe-à-Pitre
City
Pointe-à-Pitre
State/Province
Guadeloupe
ZIP/Postal Code
97139
Country
France
Facility Name
CHU Bordeaux Hôpital Pellegrin
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
CHU Limoges Hôpital Dupuytren
City
Limoges
ZIP/Postal Code
87042
Country
France
Facility Name
CHU Toulouse Hôpital Purpan
City
Toulouse
ZIP/Postal Code
31059
Country
France
12. IPD Sharing Statement
Learn more about this trial
Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia
We'll reach out to this number within 24 hrs